The cost-effectiveness of treatment of age-related macular degeneration: a review.
Age-related macular degeneration (AMD) is a disease of the retina, most often seen among people over the age of 50. The disease is typically manifested by the loss of central vision and as such represents a major threat to the quality of life to those suffering with it. This report reviewed the evidence concerning the economic impact of macular degeneration in the developed world, examining reports on direct and indirect medical costs, as well as those that have attempted to estimate non-health care costs. It also aimed to review reports of the cost-effectiveness of treatment of the disease, examining nutritional supplements, photodynamic therapy, and anti-VEGF treatments.
Kymes Steven
M
M
Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO 63110-1093, USA. kymes@vrcc.wustl.edu
D000975:Antioxidants / Q000627:therapeutic use; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D019587:Dietary Supplements; D018450:Disease Progression; D017048:Health Care Costs; D006801:Humans; D008268:Macular Degeneration / Q000191:economics* / Q000517:prevention & control / Q000628:therapy*; D010778:Photochemotherapy / Q000191:economics; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000975:Antioxidants; D042461:Vascular Endothelial Growth Factor A